Tokyo Tape
Sign in
← Olympus

Quarterly report · Q3

7733.TEDINET S100Q5QA
Period2022-04-01 → 2022-12-31
Filed2023-02-10
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥641.5bn2022-04-01 → 2022-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥224.5bn2022-10-01 → 2022-12-31dCons.Revenue IFRS (5-year summary)
Revenue¥750.1bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥547.2bn2021-04-01 → 2021-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥187.1bn2021-10-01 → 2021-12-31dCons.Revenue IFRS (5-year summary)
Operating income¥142.6bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥49.0bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Operating income¥102.2bn2021-04-01 → 2021-12-31Cons.Operating profit loss IFRS
Operating income¥31.6bn2021-10-01 → 2021-12-31dCons.Operating profit loss IFRS
Profit before tax¥139.4bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥50.0bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Profit before tax¥141.7bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥97.0bn2021-04-01 → 2021-12-31Cons.Profit loss before tax IFRS
Profit before tax¥28.6bn2021-10-01 → 2021-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥108.2bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥41.4bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥115.7bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥87.7bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥25.3bn2021-10-01 → 2021-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥108.4bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥41.4bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Net income¥87.8bn2021-04-01 → 2021-12-31Cons.Profit loss IFRS
Net income¥25.3bn2021-10-01 → 2021-12-31dCons.Profit loss IFRS
Total assets¥1.39Tat 2022-12-31Cons.Assets IFRS
Total assets¥1.36Tat 2022-03-31Cons.Assets IFRS
Total assets¥1.29Tat 2021-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥787.0bnat 2022-12-31Cons.Liabilities IFRS
Total liabilities¥846.6bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥605.6bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥511.4bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥480.3bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥395.5bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥604.5bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥510.2bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥479.1bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥175.7bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥211.3bnat 2022-12-31Cons.Cash and cash equivalents IFRS (5-year summary)
Cash & equivalents¥302.6bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥275.1bnat 2021-12-31Cons.Cash and cash equivalents IFRS (5-year summary)
Operating cash flow¥54.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥169.7bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥115.3bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥37.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥71.0bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥57.1bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥112.4bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥40.7bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥9.3bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥85.122022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥32.642022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥90.222021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥68.192021-04-01 → 2021-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥19.662021-10-01 → 2021-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥85.042022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥32.62022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥90.172021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥68.162021-04-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥19.652021-10-01 → 2021-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio43.4%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio37.6%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio37.1%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 10
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥15.3bn
jpcrp040300-q3r_E02272-000Endoscopic Solutionsreportable segmentsegment profit2022-04-01 → 2022-12-31¥110.7bn
jpcrp040300-q3r_E02272-000Otherreportable segmentsegment profit2022-04-01 → 2022-12-31−¥917m
jpcrp040300-q3r_E02272-000Therapeutic Solutionsreportable segmentsegment profit2022-04-01 → 2022-12-31¥48.1bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥157.9bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥31.7bn
jpcrp040300-q3r_E02272-000Endoscopic Solutionsreportable segmentsegment profit2021-04-01 → 2021-12-31¥91.6bn
jpcrp040300-q3r_E02272-000Otherreportable segmentsegment profit2021-04-01 → 2021-12-31−¥1.5bn
jpcrp040300-q3r_E02272-000Therapeutic Solutionsreportable segmentsegment profit2021-04-01 → 2021-12-31¥43.8bn
—segment totalsegment profit2021-04-01 → 2021-12-31¥134.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 734
ItemContextValueUnit
Intersegment sales IFRSCurrentYTDDuration_ReconcilingItemsMember-211000000JPY
Intersegment sales IFRSCurrentYTDDuration－JPY
Net sales IFRSCurrentYTDDuration_jpcrp040300-q3r_E02272-000EndoscopicSolutionsReportableSegmentMember398990000000JPY
Net sales IFRSCurrentYTDDuration_jpcrp040300-q3r_E02272-000TherapeuticSolutionsReportableSegmentMember233942000000JPY
Net sales IFRSCurrentYTDDuration_jpcrp040300-q3r_E02272-000OtherReportableSegmentMember8824000000JPY
Net sales IFRSCurrentYTDDuration_ReportableSegmentsMember641756000000JPY
Net sales IFRSCurrentYTDDuration_ReconcilingItemsMember-211000000JPY
Net sales IFRSCurrentYTDDuration641545000000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q3r_E02272-000EndoscopicSolutionsReportableSegmentMember110703000000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q3r_E02272-000TherapeuticSolutionsReportableSegmentMember48116000000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q3r_E02272-000OtherReportableSegmentMember-917000000JPY
Operating profit loss IFRSCurrentYTDDuration_ReportableSegmentsMember157902000000JPY
Operating profit loss IFRSCurrentYTDDuration_ReconcilingItemsMember-15330000000JPY
Operating profit loss IFRSCurrentYTDDuration142572000000JPY
Finance income IFRSCurrentYTDDuration2983000000JPY
Finance costs IFRSCurrentYTDDuration6185000000JPY
Profit loss before tax IFRSCurrentYTDDuration139370000000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration_jpcrp040300-q3r_E02272-000EndoscopicSolutionsReportableSegmentMember490000000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration_jpcrp040300-q3r_E02272-000TherapeuticSolutionsReportableSegmentMember－JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration_jpcrp040300-q3r_E02272-000OtherReportableSegmentMember－JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration_ReportableSegmentsMember490000000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration490000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration_jpcrp040300-q3r_E02272-000EndoscopicSolutionsReportableSegmentMember29271000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration_jpcrp040300-q3r_E02272-000TherapeuticSolutionsReportableSegmentMember14513000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration_jpcrp040300-q3r_E02272-000OtherReportableSegmentMember887000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration_ReportableSegmentsMember44671000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration_ReconcilingItemsMember4436000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration49107000000JPY
Impairment losses pl IFRSCurrentYTDDuration_jpcrp040300-q3r_E02272-000EndoscopicSolutionsReportableSegmentMember907000000JPY
Impairment losses pl IFRSCurrentYTDDuration_jpcrp040300-q3r_E02272-000TherapeuticSolutionsReportableSegmentMember401000000JPY
Impairment losses pl IFRSCurrentYTDDuration_jpcrp040300-q3r_E02272-000OtherReportableSegmentMember3000000JPY
Impairment losses pl IFRSCurrentYTDDuration_ReportableSegmentsMember1311000000JPY
Impairment losses pl IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Impairment losses pl IFRSCurrentYTDDuration1311000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-02-10
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第155期(2023年３月期)第３四半期（自　2022年10月１日　至　2022年12月31日）
Company name cover pageFilingDateInstant
Original text (Japanese)オリンパス株式会社
Company name in english cover pageFilingDateInstantOLYMPUS CORPORATION
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)取締役　代表執行役　社長兼CEO　　竹内　康雄
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都八王子市石川町2951番地
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京3340局2111番(代表)
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)経理部門バイスプレジデント　青柳　隆之
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都新宿区西新宿２丁目３番１号　新宿モノリス
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京3340局2111番(代表)
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)IR部門バイスプレジデント　櫻井　隆明
Place for public inspection cover page (text)FilingDateInstantText · Plus

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-10-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass